Annovis doubles as lead drug improves Parkinson’s

seekingalpha07-03

Shares of Annovis Bio (NYSE:ANVS) more than doubled in value on Tuesday after the company said its lead asset, buntanetap, was found to be safe and effective in improving the physical and cognitive ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2448199737?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1038411882/image_1038411882.jpg","is_english":true,"pubTime":"2024-07-03 02:30","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2448199737","market":"hk","top_or_hot":-1,"title":"Annovis doubles as lead drug improves Parkinson’s","media":"seekingalpha","content":"<div>\n<p>Shares of Annovis Bio (NYSE:ANVS) more than doubled in value on Tuesday after the company said its lead asset, buntanetap, was found to be safe and effective in improving the physical and cognitive ...</p>\n\n<a href=\"https://seekingalpha.com/news/4121821-annovis-stock-jumps-data-parkinsons-drug\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Annovis doubles as lead drug improves Parkinson’s</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnnovis doubles as lead drug improves Parkinson’s\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-03 02:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4121821-annovis-stock-jumps-data-parkinsons-drug><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Annovis Bio (NYSE:ANVS) more than doubled in value on Tuesday after the company said its lead asset, buntanetap, was found to be safe and effective in improving the physical and cognitive ...</p>\n\n<a href=\"https://seekingalpha.com/news/4121821-annovis-stock-jumps-data-parkinsons-drug\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://seekingalpha.com/news/4121821-annovis-stock-jumps-data-parkinsons-drug","article_id":"2448199737","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1038411882/image_1038411882.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2448199737","pubTimestamp":1719945051,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Shares of Annovis Bio  more than doubled in value on Tuesday after the company said its lead asset, buntanetap, was found to be safe and effective in improving the physical and cognitive functions of patients with early Parkinson’s disease. Updating data from its Phase 3 PD trial, Annovis  said buntanetap, designed to target neurotoxic proteins, maintained cognition in the entire patient population at 10 and 20 mg doses, while those on placebo deteriorated throughout the study. At 20 mg, the study drug “showed significant improvement in cognition compared to placebo,” the company added. With a consistent tolerability profile across early and advanced PD patients, buntanetap led to statistically significant improvements in all primary and secondary endpoints in specific subgroups, according to Annovis Bio . The company has scheduled a webcast at 4:30 PM ET on July 2 to discuss additional results.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ANVS":"Annovis Bio, Inc."},"translate_title":"Annovis是改善帕金森病的主要药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANVS":1},"content_text":"Shares of Annovis Bio (NYSE:ANVS) more than doubled in value on Tuesday after the company said its lead asset, buntanetap, was found to be safe and effective in improving the physical and cognitive functions of patients with early Parkinson’s disease. Updating data from its Phase 3 PD trial, Annovis (ANVS) said buntanetap, designed to target neurotoxic proteins, maintained cognition in the entire patient population at 10 and 20 mg doses, while those on placebo deteriorated throughout the study. At 20 mg, the study drug “showed significant improvement in cognition compared to placebo,” the company added. With a consistent tolerability profile across early and advanced PD patients, buntanetap led to statistically significant improvements in all primary and secondary endpoints in specific subgroups, according to Annovis Bio (ANVS). The company has scheduled a webcast at 4:30 PM ET on July 2 to discuss additional results.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2448199737"}